Home » General World News » Novartis is going after a $5 billion market with a new treatment for vision loss. That’s a big threat to Regeneron

Novartis is going after a $5 billion market with a new treatment for vision loss. That’s a big threat to Regeneron





Novartis CEO Vas Narasimhan

  • Novartis’ drug brolucizumab just showed that it wasn’t any worse than a rival drug called Eylea at treating an eye condition known as age-related macular degeneration.
  • It confirmed what the company had previously found after one year, that Novartis’ drug was also better at reducing retinal thickness and retinal fluid compared to Eylea, two factors that are key in reducing the symptoms of the disease.
  • Novartis plans to submit brolucizumab for FDA review by the end of 2018.

Novartis is gearing up to shake up a huge eye-drug market.

In data presented Saturday at the American Academy of Ophthalmology annual read more >>>

Source:: BusinessInsider.Com

Comments are closed.